ApoE Genetic Testing To Estimate a Person’s Risk of Developing AD By Gabrielle Strobel Genetic and epidemiologic studies have confirmed ApoE to be the strongest known genetic risk factor for common late-onset AD. Having inherited a single ApoE ε4 variant increases one’s risk of developing AD by a factor of three in men and four [...]
My research practice started in 1987, many years before the NJ Alzheimer’s Association Chapter even was in it’s planning stage. The biggest challenge facing me and the stuy enrollment was access to interested patients and their loved ones. Lecturing to community centers, being invited to talk at houses of worship, going to senior centers, assisted [...]
There might be very soon (perhaps in 2012) a new study which will try to reduce the hippocampus from shrinking in those individuals who carry ApoE4. Such individuals with or without a family history of dementia are high risk to develop such shrinkage of their hippocampi (the area of the brain where new memories are [...]
This information below is taken from a link from Merck’s recent presentation on it’s AD pipeline. A BACE inhibitor acts to inhibit the production of toxic amyloid beta peptides that are 42 amino long. It is currently under intense debate whether there should be drugs targeting any amount of amyloid in the brain. I believe [...]
December 1, 2011 Ocean County –Dr. Joel S. Ross, President and Founder of Memory Enhancement Center of America, Inc., with offices in Toms River and Eatontown, has been named the “Alzheimer’s Respite Care Program (ARCP) 2011 Humanitarian of the Year” by Caregiver Volunteers of Central Jersey (CVCJ). The honor will be given at the Annual [...]
« Previous EntriesNext Entries »